Replies to post #5703 on Momenta Pharmaceuticals, Inc. (MNTA)

[Regulardoc]

Another very weak positive of today's news is that I hope this puts the nail in the M 118 coffin and MNTA does not attempt trials on its own dime.

I am concerned about a point that Dew made earlier, as far as the value of MNTA's science and propietary technology. If another company can truly design and characterize and manufacture complex molecules via a different mechanism, how much is MNTA's science worth? Given the way MNTA was able to leapfrog Amphastar in the approval process, I am hoping it has significant value; however, if Amphastar has its own homegrown technology (that has now proven to be quite capable) how does one view and value MNTA's investment in complex characterization methodology?

[HattieTheWitch]

I do have to agree with tinker that as bad as today's news are, it is actually very positive for mCopax..

Can you expand on your thought process?

Thank you.